Changing epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa

James E. Scriven; David Lalloo; Graeme Meintjes

doi:10.1016/s1473-3099(16)30145-1

Changing epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa

James E. Scriven
, David Lalloo
, Graeme Meintjes

Liverpool School of Tropical Medicine
Wellcome Trust
University of Cape Town
Imperial College London

Research output: Contribution to journal › Letter › peer-review

15 Citations (Scopus)

Abstract

We read with interest the recent dose-finding study by Joshua Rhein and colleagues1 examining the use of sertraline alongside amphotericin B in the treatment of HIV-associated cryptococcal meningitis, and agree that further clinical trials are required to assess the possible benefit of this therapy. As noted in the linked Comment, cryptococcosis has not disappeared following the rollout of antiretroviral therapy (ART); 53% of the participants enrolled in the sertraline study were taking ART, suggesting a change in the epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa during the past 5–10 years.

Original language	English
Pages (from-to)	891-892
Number of pages	2
Journal	The Lancet Infectious Diseases
Volume	16
Issue number	8
DOIs	https://doi.org/10.1016/s1473-3099(16)30145-1
Publication status	Published - 19 Jul 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/s1473-3099(16)30145-1

Lancet 2016 16 18 p891-892Accepted author manuscript, 12.4 MBLicence: CC BY-NC-SA

Cite this

@article{682a189a090f4f27841a9f237fed83ad,

title = "Changing epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa",

abstract = "We read with interest the recent dose-finding study by Joshua Rhein and colleagues1 examining the use of sertraline alongside amphotericin B in the treatment of HIV-associated cryptococcal meningitis, and agree that further clinical trials are required to assess the possible benefit of this therapy. As noted in the linked Comment, cryptococcosis has not disappeared following the rollout of antiretroviral therapy (ART); 53\% of the participants enrolled in the sertraline study were taking ART, suggesting a change in the epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa during the past 5–10 years.",

author = "Scriven, \{James E.\} and David Lalloo and Graeme Meintjes",

year = "2016",

month = jul,

day = "19",

doi = "10.1016/s1473-3099(16)30145-1",

language = "English",

volume = "16",

pages = "891--892",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Changing epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa

AU - Scriven, James E.

AU - Lalloo, David

AU - Meintjes, Graeme

PY - 2016/7/19

Y1 - 2016/7/19

N2 - We read with interest the recent dose-finding study by Joshua Rhein and colleagues1 examining the use of sertraline alongside amphotericin B in the treatment of HIV-associated cryptococcal meningitis, and agree that further clinical trials are required to assess the possible benefit of this therapy. As noted in the linked Comment, cryptococcosis has not disappeared following the rollout of antiretroviral therapy (ART); 53% of the participants enrolled in the sertraline study were taking ART, suggesting a change in the epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa during the past 5–10 years.

AB - We read with interest the recent dose-finding study by Joshua Rhein and colleagues1 examining the use of sertraline alongside amphotericin B in the treatment of HIV-associated cryptococcal meningitis, and agree that further clinical trials are required to assess the possible benefit of this therapy. As noted in the linked Comment, cryptococcosis has not disappeared following the rollout of antiretroviral therapy (ART); 53% of the participants enrolled in the sertraline study were taking ART, suggesting a change in the epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa during the past 5–10 years.

U2 - 10.1016/s1473-3099(16)30145-1

DO - 10.1016/s1473-3099(16)30145-1

M3 - Letter

SN - 1473-3099

VL - 16

SP - 891

EP - 892

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 8

ER -

Changing epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this